Docetaxel vs Ixabepilone

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

HR+/HER2- Metastatic Breast Cancer

Shared mechanism: Microtubules (tubulin) · full HR+/HER2- Metastatic Breast Cancer pipeline

Docetaxel · Taxotere

Marketed by Sanofi

Approved in HR+/HER2- Metastatic Breast Cancersmall molecule
Partial signal

NCT00002662 · Phase 3 · completed

The study used randomization and an active treatment comparator, but it was open-label and the registry does not report its sample size, primary endpoint, or results. Without posted outcome data, the trial provides only limited evidence about the comparative effects of docetaxel and paclitaxel.

Next expected readout: December 2026 · NCT04140526 (registry estimate)

Reported efficacy

ORR (the registered first objective) 32% vs 25% (P=.10); OS 15.4 vs 12.7 months (P=.03) and TTP 5.7 vs 3.6 months (P<.0001) favored docetaxel. (missed)

Result source: NCT00002662

Ixabepilone

Marketed by R-Pharm

Approved in HR+/HER2- Metastatic Breast Cancersmall molecule
Partial signal

NCT00080301 · Phase 3 · completed

The trial randomized 752 participants to ixabepilone plus capecitabine or capecitabine alone and used progression-free survival, a hard clinical endpoint, as its primary outcome. The primary comparison favored the combination, but the study was open-label rather than double-blind; overall survival, a secondary endpoint, was not significantly improved.

Reported efficacy

Progression-free Survival (PFS) Per Independent Radiology Review Committee (IRRC) (based on assessments every 6 weeks while on treatment until documented disease progression/unacceptable toxicity): Progression-free Survival (PFS) Per Independent Radiology Review Committee (IRRC) (based on assessments every 6 weeks while on treatment until documented disease progression/unacceptable toxicity): Ixabepilone + Capecitabine 5.85 Months (95% CI 5.45 to 6.97) | Capecitabine 4.17 Months (95% CI 3.81 to 4.5) (met)

Result source: NCT00080301

Results for HR+/HER2- Metastatic Breast Cancer

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointDocetaxelIxabepilone
PFS, median9.5 vs 8.2+1.3 vs placebon 759NCT00703326
10 other results
—Not reported
OS, median30.3 vs 28.7+1.6 vs placebon 759NCT00703326
6 other results
—Not reported
ORR44.7% vs 37.9%+6.8 vs placebon 759NCT00703326
5 other results
—Not reported
Clinical benefit rate60.4% vs 62%vs Trastuzumabn 326NCT00667251
2 other results
—Not reported

PFS, median

Docetaxel
9.5 vs 8.2+1.3 vs placebon 759NCT00703326
10 other results
Ixabepilone
—Not reported

OS, median

Docetaxel
30.3 vs 28.7+1.6 vs placebon 759NCT00703326
6 other results
Ixabepilone
—Not reported

ORR

Docetaxel
44.7% vs 37.9%+6.8 vs placebon 759NCT00703326
5 other results
Ixabepilone
—Not reported

Clinical benefit rate

Docetaxel
60.4% vs 62%vs Trastuzumabn 326NCT00667251
2 other results
Ixabepilone
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Ixabepilone: registry results are on file for HR+/HER2- Metastatic Breast Cancer, but their comparison mappings are not yet available.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. Docetaxel: 4 of 4 rows · Ixabepilone: 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricDocetaxel
Dropout rate
8.6%Trastuzumab With AC-TH Regimena
NCT02419742 · Phase 4 · registry result, not featured evidence · combination
show 31 more results
3.8%Trastuzumab With TCH Regimen
NCT02419742 · Phase 4 · registry result, not featured evidence · combination
75%
NCT02445586 · Phase 4 · registry result, not featured evidence · combination
n/a: no completion milestoneLapatinib (LTax/L)
NCT00667251 · Phase 3 · registry result, not featured evidence
—Lapatinib (LTax/L) - All Participa
NCT00667251 · Phase 3 · registry result, not featured evidence
5%
NCT02586025 · Phase 3 · registry result, not featured evidence
52.3%
NCT03084237 · Phase 3 · registry result, not featured evidence · combination
13.4%
NCT00703326 · Phase 3 · registry result, not featured evidence · combination
69%
NCT01572038 · Phase 3 · registry result, not featured evidence · combination
18.6%
NCT02953340 · Phase 3 · registry result, not featured evidence · combination
—
NCT02643420 · Phase 3 · registry result, not featured evidence · combination
11.1%Trastuzumab (AryoTrust)
NCT03425656 · Phase 3 · registry result, not featured evidence
—Trastuzumab (AryoTrust) / ACTH
NCT03425656 · Phase 3 · registry result, not featured evidence · combination
—
NCT02472964 · Phase 3 · registry result, not featured evidence · combination
15.1%Trastuzumab (SID)
NCT01940497 · Phase 3 · registry result, not featured evidence
—Trastuzumab (SID) Adjuvant
NCT01940497 · Phase 3 · registry result, not featured evidence
—Trastuzumab (SID) Neoadjuvant
NCT01940497 · Phase 3 · registry result, not featured evidence
17.4%Trastuzumab (Vial)
NCT01940497 · Phase 3 · registry result, not featured evidence
—Trastuzumab (Vial): Adjuvant
NCT01940497 · Phase 3 · registry result, not featured evidence
—Trastuzumab (Vial): Neoadjuvant
NCT01940497 · Phase 3 · registry result, not featured evidence
25.1%AC Followed by Docetaxel + Hercept
NCT00021255 · Phase 3 · registry result, not featured evidence · combination
13.9%Docetaxel + Carboplatin + Hercepti
NCT00021255 · Phase 3 · registry result, not featured evidence · combination
n/a: no completion milestoneDocetaxel 100 mg/m^2 Plus Bevacizu
NCT00333775 · Phase 3 · registry result, not featured evidence · combination
n/a: no completion milestoneDocetaxel 100 mg/m^2 Plus Bevacizu
NCT00333775 · Phase 3 · registry result, not featured evidence · combination
64.8%
NCT00191152 · Phase 3 · registry result, not featured evidence · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
20.6%Cohort A: ddAC, Paclitaxel, Pertuz
NCT02132949 · Phase 2 · registry result, not featured evidence · combination
13.9%Cohort B: FEC, Docetaxel, Pertuzum
NCT02132949 · Phase 2 · registry result, not featured evidence · combination
18.4%
NCT01446016 · Phase 2 · registry result, not featured evidence · combination
—
NCT01527487 · Phase 2 · registry result, not featured evidence · combination
—
NCT00068341 · Phase 2 · registry result, not featured evidence · combination
16%
NCT00179309 · Phase 2 · registry result, not featured evidence · combination
28.2%
NCT00054275 · Phase 2 · registry result, not featured evidence · combination
Discontinued due to AEs
3.4%Trastuzumab With AC-TH Regimena
NCT02419742 · Phase 4 · registry result, not featured evidence · combination
show 31 more results
0%Trastuzumab With TCH Regimen
NCT02419742 · Phase 4 · registry result, not featured evidence · combination
—
NCT02445586 · Phase 4 · registry result, not featured evidence · combination
—Lapatinib (LTax/L)
NCT00667251 · Phase 3 · registry result, not featured evidence
—Lapatinib (LTax/L) - All Participa
NCT00667251 · Phase 3 · registry result, not featured evidence
0.5%
NCT02586025 · Phase 3 · registry result, not featured evidence
—
NCT03084237 · Phase 3 · registry result, not featured evidence · combination
0.1%
NCT00703326 · Phase 3 · registry result, not featured evidence · combination
—
NCT01572038 · Phase 3 · registry result, not featured evidence · combination
—
NCT02953340 · Phase 3 · registry result, not featured evidence · combination
—
NCT02643420 · Phase 3 · registry result, not featured evidence · combination
—Trastuzumab (AryoTrust)
NCT03425656 · Phase 3 · registry result, not featured evidence
—Trastuzumab (AryoTrust) / ACTH
NCT03425656 · Phase 3 · registry result, not featured evidence · combination
—
NCT02472964 · Phase 3 · registry result, not featured evidence · combination
6.7%Trastuzumab (SID)
NCT01940497 · Phase 3 · registry result, not featured evidence
—Trastuzumab (SID) Adjuvant
NCT01940497 · Phase 3 · registry result, not featured evidence
—Trastuzumab (SID) Neoadjuvant
NCT01940497 · Phase 3 · registry result, not featured evidence
9.1%Trastuzumab (Vial)
NCT01940497 · Phase 3 · registry result, not featured evidence
—Trastuzumab (Vial): Adjuvant
NCT01940497 · Phase 3 · registry result, not featured evidence
—Trastuzumab (Vial): Neoadjuvant
NCT01940497 · Phase 3 · registry result, not featured evidence
2.8%AC Followed by Docetaxel + Hercept
NCT00021255 · Phase 3 · registry result, not featured evidence · combination
1.7%Docetaxel + Carboplatin + Hercepti
NCT00021255 · Phase 3 · registry result, not featured evidence · combination
—Docetaxel 100 mg/m^2 Plus Bevacizu
NCT00333775 · Phase 3 · registry result, not featured evidence · combination
—Docetaxel 100 mg/m^2 Plus Bevacizu
NCT00333775 · Phase 3 · registry result, not featured evidence · combination
28.4%
NCT00191152 · Phase 3 · registry result, not featured evidence · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
1%Cohort A: ddAC, Paclitaxel, Pertuz
NCT02132949 · Phase 2 · registry result, not featured evidence · combination
0.5%Cohort B: FEC, Docetaxel, Pertuzum
NCT02132949 · Phase 2 · registry result, not featured evidence · combination
—
NCT01446016 · Phase 2 · registry result, not featured evidence · combination
—
NCT01527487 · Phase 2 · registry result, not featured evidence · combination
—
NCT00068341 · Phase 2 · registry result, not featured evidence · combination
—
NCT00179309 · Phase 2 · registry result, not featured evidence · combination
12.8%
NCT00054275 · Phase 2 · registry result, not featured evidence · combination
Serious AEs
19.6%Trastuzumab With AC-TH Regimena
NCT02419742 · Phase 4 · registry result, not featured evidence · combination
show 31 more results
17.3%Trastuzumab With TCH Regimen
NCT02419742 · Phase 4 · registry result, not featured evidence · combination
59.6%
NCT02445586 · Phase 4 · registry result, not featured evidence · combination
—Lapatinib (LTax/L)
NCT00667251 · Phase 3 · registry result, not featured evidence
32.9%Lapatinib (LTax/L) - All Participa
NCT00667251 · Phase 3 · registry result, not featured evidence
17%
NCT02586025 · Phase 3 · registry result, not featured evidence
24%
NCT03084237 · Phase 3 · registry result, not featured evidence · combination
37.9%
NCT00703326 · Phase 3 · registry result, not featured evidence · combination
37.3%
NCT01572038 · Phase 3 · registry result, not featured evidence · combination
10.3%
NCT02953340 · Phase 3 · registry result, not featured evidence · combination
18.3%
NCT02643420 · Phase 3 · registry result, not featured evidence · combination
—Trastuzumab (AryoTrust)
NCT03425656 · Phase 3 · registry result, not featured evidence
0%Trastuzumab (AryoTrust) / ACTH
NCT03425656 · Phase 3 · registry result, not featured evidence · combination
39.3%
NCT02472964 · Phase 3 · registry result, not featured evidence · combination
—Trastuzumab (SID)
NCT01940497 · Phase 3 · registry result, not featured evidence
7.6%Trastuzumab (SID) Adjuvant
NCT01940497 · Phase 3 · registry result, not featured evidence
9.5%Trastuzumab (SID) Neoadjuvant
NCT01940497 · Phase 3 · registry result, not featured evidence
—Trastuzumab (Vial)
NCT01940497 · Phase 3 · registry result, not featured evidence
5.3%Trastuzumab (Vial): Adjuvant
NCT01940497 · Phase 3 · registry result, not featured evidence
15%Trastuzumab (Vial): Neoadjuvant
NCT01940497 · Phase 3 · registry result, not featured evidence
27.1%AC Followed by Docetaxel + Hercept
NCT00021255 · Phase 3 · registry result, not featured evidence · combination
26.8%Docetaxel + Carboplatin + Hercepti
NCT00021255 · Phase 3 · registry result, not featured evidence · combination
46%Docetaxel 100 mg/m^2 Plus Bevacizu
NCT00333775 · Phase 3 · registry result, not featured evidence · combination
42.1%Docetaxel 100 mg/m^2 Plus Bevacizu
NCT00333775 · Phase 3 · registry result, not featured evidence · combination
24.3%
NCT00191152 · Phase 3 · registry result, not featured evidence · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
28.1%Cohort A: ddAC, Paclitaxel, Pertuz
NCT02132949 · Phase 2 · registry result, not featured evidence · combination
33.3%Cohort B: FEC, Docetaxel, Pertuzum
NCT02132949 · Phase 2 · registry result, not featured evidence · combination
2.6%
NCT01446016 · Phase 2 · registry result, not featured evidence · combination
7.4%
NCT01527487 · Phase 2 · registry result, not featured evidence · combination
40%
NCT00068341 · Phase 2 · registry result, not featured evidence · combination
12%
NCT00179309 · Phase 2 · registry result, not featured evidence · combination
71.8%
NCT00054275 · Phase 2 · registry result, not featured evidence · combination
Most frequent reported AEs
a
leukopenia 39.3%
urinary tract infection 25%
anaemia 21.4%
NCT02419742 · Phase 4 · registry result, not featured evidence · combination
show 27 more results
anaemia 51.9%
thrombocytopenia 42.3%
asthenia 23.1%
NCT02419742 · Phase 4 · registry result, not featured evidence · combination
diarrhoea 32.7%
anaemia 15.4%
fatigue 15.4%
NCT02445586 · Phase 4 · registry result, not featured evidence · combination
diarrhoea 77.6%
fatigue 69.9%
alopecia 65.8%
NCT00667251 · Phase 3 · registry result, not featured evidence
neutropenia 70.2% (placebo 66.4%)
leukopenia 61.9% (placebo 60.9%)
alopecia 52.8% (placebo 50.9%)
NCT02586025 · Phase 3 · registry result, not featured evidence
white blood cell count decreased 82.2%
neutrophil count decreased 81.8%
alopecia 55.7%
NCT03084237 · Phase 3 · registry result, not featured evidence · combination
alopecia 71.1% (placebo 73%)
stomatitis 50.5% (placebo 30.9%)
diarrhoea 43.4% (placebo 39.8%)
NCT00703326 · Phase 3 · registry result, not featured evidence · combination
diarrhoea 67.8%
alopecia 48.3%
nausea 35.7%
NCT01572038 · Phase 3 · registry result, not featured evidence · combination
nausea 42.7%
bone pain 40.2%
lymphocyte count decreased 37.6%
NCT02953340 · Phase 3 · registry result, not featured evidence · combination
fatigue 60.9%
nausea 56.9%
alopecia 48.2%
NCT02643420 · Phase 3 · registry result, not featured evidence · combination
alopecia 48.1%
anaemia 24.1%
blood alkaline phosphatase increased 5.6%
NCT03425656 · Phase 3 · registry result, not featured evidence · combination
alopecia 57.9%
neutropenia 36.8%
asthenia 23.1%
NCT02472964 · Phase 3 · registry result, not featured evidence · combination
arthralgia 30.4%
paraesthesia 27.2%
asthenia 21.7%
NCT01940497 · Phase 3 · registry result, not featured evidence
asthenia 33.3%
diarrhoea 28.6%
arthralgia 23.8%
NCT01940497 · Phase 3 · registry result, not featured evidence
paraesthesia 51.6%
asthenia 33.7%
arthralgia 30.5%
NCT01940497 · Phase 3 · registry result, not featured evidence
hot flush 25%
hypertension 25%
arthralgia 20%
NCT01940497 · Phase 3 · registry result, not featured evidence
alopecia 98.5%
nausea 87.9%
asthenia 84.1%
NCT00021255 · Phase 3 · registry result, not featured evidence · combination
alopecia 96.4%
asthenia 83.1%
nausea 81.7%
NCT00021255 · Phase 3 · registry result, not featured evidence · combination
alopecia 70.1% (placebo 71%)
diarrhoea 53.6% (placebo 48.8%)
nausea 50.6% (placebo 53.9%)
NCT00333775 · Phase 3 · registry result, not featured evidence · combination
alopecia 71.8% (placebo 71%)
diarrhoea 56.7% (placebo 48.8%)
stomatitis 50.4% (placebo 27.6%)
NCT00333775 · Phase 3 · registry result, not featured evidence · combination
palmar-plantar erythrodysaesthesia syndrome 57.1%
fatigue 53.1%
nausea 52.2%
NCT00191152 · Phase 3 · registry result, not featured evidence · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
nausea 72.4%
diarrhoea 71.9%
alopecia 63.8%
NCT02132949 · Phase 2 · registry result, not featured evidence · combination
nausea 71.7%
diarrhoea 71.2%
alopecia 59.1%
NCT02132949 · Phase 2 · registry result, not featured evidence · combination
fatigue 5.3%
back pain 2.6%
dehydration 2.6%
NCT01446016 · Phase 2 · registry result, not featured evidence · combination
fatigue 74.1%
nausea 61.1%
alopecia 59.3%
NCT01527487 · Phase 2 · registry result, not featured evidence · combination
anemia 86.7%
leukopenia 86.7%
nausea 86.7%
NCT00068341 · Phase 2 · registry result, not featured evidence · combination
injection site reaction 68%
fatigue 64%
alopecia 60%
NCT00179309 · Phase 2 · registry result, not featured evidence · combination
fatigue 94.9%
anemia 71.8%
anorexia 71.8%
NCT00054275 · Phase 2 · registry result, not featured evidence · combination

Notes

  1. aPopulation comparability has not been reviewed for 31 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Docetaxel

Disease-free Survival NA months
time to event · months
No placebo or comparator arm
NCT02419742 · Phase 4 · registry result, not featured evidence · combination
show 5 more results
NA months
NCT02419742 · Phase 4 · registry result, not featured evidence · combination
NA months
NCT01940497 · Phase 3 · registry result, not featured evidence
NA months
NCT01940497 · Phase 3 · registry result, not featured evidence
NA months
NCT01940497 · Phase 3 · registry result, not featured evidence
NA months
NCT01940497 · Phase 3 · registry result, not featured evidence
Overall Survival NA months
time to event · months
No placebo or comparator arm
NCT02419742 · Phase 4 · registry result, not featured evidence · combination
show 9 more results
NA months
NCT02419742 · Phase 4 · registry result, not featured evidence · combination
NA months
NCT02445586 · Phase 4 · registry result, not featured evidence · combination
65.31 months
NCT01572038 · Phase 3 · registry result, not featured evidence · combination
NA months
NCT01940497 · Phase 3 · registry result, not featured evidence
NA months
NCT01940497 · Phase 3 · registry result, not featured evidence
NA months
NCT01940497 · Phase 3 · registry result, not featured evidence
NA months
NCT01940497 · Phase 3 · registry result, not featured evidence
25.4 months
NCT01446016 · Phase 2 · registry result, not featured evidence · combination
22.3 months
NCT00054275 · Phase 2 · registry result, not featured evidence · combination
ORR 82.7% (n=52)
responder rate · % of participants
No placebo or comparator arm
Responders (ORR)
NCT02445586 · Phase 4 · registry result, not featured evidence · combination
PFS 23 months
time to event · months
No placebo or comparator arm
NCT02445586 · Phase 4 · registry result, not featured evidence · combination
show 3 more results
20.67 months
NCT01572038 · Phase 3 · registry result, not featured evidence · combination
12.4 months
NCT01446016 · Phase 2 · registry result, not featured evidence · combination
8.4 months
NCT00054275 · Phase 2 · registry result, not featured evidence · combination
PFS 98.08% (n=52) @ 8.67wk
absolute value · percentage points
No placebo or comparator arm
NCT02445586 · Phase 4 · registry result, not featured evidence · combination
show 19 more results
96.15% (n=52) @ 13wk
NCT02445586 · Phase 4 · registry result, not featured evidence · combination
90.27% (n=52) @ 21.67wk
NCT02445586 · Phase 4 · registry result, not featured evidence · combination
88.3% (n=52) @ 26wk
NCT02445586 · Phase 4 · registry result, not featured evidence · combination
82.42% (n=52) @ 30.33wk
NCT02445586 · Phase 4 · registry result, not featured evidence · combination
78.49% (n=52) @ 34.67wk
NCT02445586 · Phase 4 · registry result, not featured evidence · combination
74.57% (n=52) @ 39wk
NCT02445586 · Phase 4 · registry result, not featured evidence · combination
68.52% (n=52) @ 47.67wk
NCT02445586 · Phase 4 · registry result, not featured evidence · combination
64.49% (n=52) @ 56.33wk
NCT02445586 · Phase 4 · registry result, not featured evidence · combination
60.33% (n=52) @ 65wk
NCT02445586 · Phase 4 · registry result, not featured evidence · combination
58.1% (n=52) @ 69.33wk
NCT02445586 · Phase 4 · registry result, not featured evidence · combination
55.86% (n=52) @ 73.67wk
NCT02445586 · Phase 4 · registry result, not featured evidence · combination
53.63% (n=52) @ 78wk
NCT02445586 · Phase 4 · registry result, not featured evidence · combination
51.3% (n=52) @ 82.33wk
NCT02445586 · Phase 4 · registry result, not featured evidence · combination
48.96% (n=52) @ 99.67wk
NCT02445586 · Phase 4 · registry result, not featured evidence · combination
46.63% (n=52) @ 104wk
NCT02445586 · Phase 4 · registry result, not featured evidence · combination
41.72% (n=52) @ 108.33wk
NCT02445586 · Phase 4 · registry result, not featured evidence · combination
36.16% (n=52) @ 117wk
NCT02445586 · Phase 4 · registry result, not featured evidence · combination
32.87% (n=52) @ 125.67wk
NCT02445586 · Phase 4 · registry result, not featured evidence · combination
29.59% (n=52) @ 138.67wk
NCT02445586 · Phase 4 · registry result, not featured evidence · combination
Overall Survival 96.15% (n=52) @ 13wk
absolute value · percentage points
No placebo or comparator arm
NCT02445586 · Phase 4 · registry result, not featured evidence · combination
show 23 more results
88.3% (n=52) @ 39wk
NCT02445586 · Phase 4 · registry result, not featured evidence · combination
88.3% (n=52) @ 56.33wk
NCT02445586 · Phase 4 · registry result, not featured evidence · combination
88.3% (n=52) @ 60.67wk
NCT02445586 · Phase 4 · registry result, not featured evidence · combination
88.3% (n=52) @ 65wk
NCT02445586 · Phase 4 · registry result, not featured evidence · combination
83.66% (n=52) @ 78wk
NCT02445586 · Phase 4 · registry result, not featured evidence · combination
83.66% (n=52) @ 82.33wk
NCT02445586 · Phase 4 · registry result, not featured evidence · combination
83.66% (n=52) @ 86.67wk
NCT02445586 · Phase 4 · registry result, not featured evidence · combination
81.12% (n=52) @ 104wk
NCT02445586 · Phase 4 · registry result, not featured evidence · combination
81.12% (n=52) @ 108.33wk
NCT02445586 · Phase 4 · registry result, not featured evidence · combination
68.14% (n=52) @ 117wk
NCT02445586 · Phase 4 · registry result, not featured evidence · combination
68.14% (n=52) @ 138.67wk
NCT02445586 · Phase 4 · registry result, not featured evidence · combination
64.36% (n=52) @ 143wk
NCT02445586 · Phase 4 · registry result, not featured evidence · combination
64.36% (n=52) @ 147.33wk
NCT02445586 · Phase 4 · registry result, not featured evidence · combination
99.48% (n=199) @ 52wk
NCT02132949 · Phase 2 · registry result, not featured evidence · combination
100% (n=201) @ 52wk
NCT02132949 · Phase 2 · registry result, not featured evidence · combination
98.96% (n=199) @ 104wk
NCT02132949 · Phase 2 · registry result, not featured evidence · combination
97.94% (n=201) @ 104wk
NCT02132949 · Phase 2 · registry result, not featured evidence · combination
97.86% (n=199) @ 156wk
NCT02132949 · Phase 2 · registry result, not featured evidence · combination
96.38% (n=201) @ 156wk
NCT02132949 · Phase 2 · registry result, not featured evidence · combination
97.86% (n=199) @ 208wk
NCT02132949 · Phase 2 · registry result, not featured evidence · combination
94.81% (n=201) @ 208wk
NCT02132949 · Phase 2 · registry result, not featured evidence · combination
96.1% (n=199) @ 260wk
NCT02132949 · Phase 2 · registry result, not featured evidence · combination
93.75% (n=201) @ 260wk
NCT02132949 · Phase 2 · registry result, not featured evidence · combination
PFS 8.97 vs 11.3 Trastuzumab months
time to event · months
Intent-to-Treat (ITT) population
NCT00667251 · Phase 3 · registry result, not featured evidence
show 1 more result
9.1 vs 11.5 Trastuzumab months
Intent-to-Treat (ITT) population
NCT00667251 · Phase 3 · registry result, not featured evidence
Overall Survival NA vs NA placebo months
time to event · months
NCT00333775 · Phase 3 · registry result, not featured evidence · combination
show 5 more results
NA vs NA placebo months
NCT00333775 · Phase 3 · registry result, not featured evidence · combination
30 vs 38.3 Trastuzumab months
NCT00667251 · Phase 3 · registry result, not featured evidence
30 vs NA Trastuzumab months
NCT00667251 · Phase 3 · registry result, not featured evidence
30.3 vs 28.7 placebo months
NCT00703326 · Phase 3 · registry result, not featured evidence · combination
23.29 vs 22.99 Gemcitabine Plus Docetaxel months
NCT00191152 · Phase 3 · registry result, not featured evidence · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
CNS Progression 14.4% (n=326) vs 16.9% (n=326) Trastuzumab
event count · % of participants
Subject had CNS metastasis at first progression = Yes
NCT00667251 · Phase 3 · registry result, not featured evidence · converted to % from 47 Participants as posted
show 1 more result
15.9% (n=270) vs 18.7% (n=267) Trastuzumab*
Subject had CNS metastasis at first progression = Yes
NCT00667251 · Phase 3 · registry result, not featured evidence · converted to % from 43 Participants as posted
Time to CNS Progression NA vs NA Trastuzumab months
time to event · months
NCT00667251 · Phase 3 · registry result, not featured evidence
show 1 more result
NA vs NA Trastuzumab months
NCT00667251 · Phase 3 · registry result, not featured evidence
ORR 64.2% (n=326) vs 63.3% (n=326) Trastuzumab
responder rate · % of participants
NCT00667251 · Phase 3 · registry result, not featured evidence
show 3 more results
66.7% (n=270) vs 67.4% (n=267) Trastuzumab
NCT00667251 · Phase 3 · registry result, not featured evidence
88.6% (n=219) vs 78.2% (n=110) placebo @ 13wk
NCT02586025 · Phase 3 · registry result, not featured evidence
44.7% (n=759) vs 37.9% (n=385) placebo
NCT00703326 · Phase 3 · registry result, not featured evidence · combination
Clinical Benefit 60.4% (n=326) vs 62% (n=326) Trastuzumab
responder rate · % of participants
NCT00667251 · Phase 3 · registry result, not featured evidence
show 1 more result
61.1% (n=270) vs 65.2% (n=267) Trastuzumab
NCT00667251 · Phase 3 · registry result, not featured evidence

+ 223 further endpoints in the CSV export.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Docetaxel's landscape · Ixabepilone's landscape